Larka

M&A

Either you're looking to buy or sell an asset in the pharma & biotech industry, Larka will provide the expertise you need.

 

M&A


Decades of experience in the pharmaceutical & biotech industry combined with strong expertise in M&A operations allow us to support either buyers in defining levers of value creation, or sellers to maximise their bargaining position.
 
 

Buy-Side

Larka industry-specific expertise provides buyers with a critical review of the target business top-line and the cost structure consistency for both past data and forecasts, as well as an objective and realistic approach of the value creation potential.

  • Identification of potential targets
  • Acquisition strategy definition
  • Target market and competitive environment
  • Target assessment based on Larka data and public information – due-diligence preparation
  • Due-diligence
    • Analytical review of all available information: data room, Vendor Due-Diligence - portfolio, technologies, competitive positioning, cost structure, sales & profitability, resources allocation, customer portfolio & pipeline, target positioning & business plan, strategy, management and operations
    • Site audit: technological capabilities, quality, HSE, human resources, expertise and know-how, asset synergies
  • Integration and separation issues
  • Strategy and management business plan, identification of levers of value creation
  • Post acquisition integration and strategy implementation

Sell-Side - Technical, Commercial & Operational VDD

An independent analysis and assessment with a full control over the type and scope of information being disclosed.

  • Corporate valuation
  • Commercial & Strategic VDD
    • Market structure, competitive environment and drivers
    • Products or businesses portfolio & pipeline
    • Customer portfolio, sales and volumes
    • Competitive positioning, customers & suppliers feedback
    • Business plan, scenario and forecast
    • Build & Buy strategy
  • Technical VDD
    • Innovation – R&D capabilities & technologies, products pipeline
    • Manufacturing and packaging capabilities, product portfolio
    • Identification of key assets, process improvement and optimisation
    • Quality and HSE environment
    • Supply chain
  • Operational VDD
    • Resources allocation and organisation structure
    • Assets and contracts
    • Procurement
    • Intellectual Property
    • Integration or separation issues, solutions and financial impacts
    • Post-acquisition transitional terms preliminary preparation

 

Other Topics

 

Customer Experience

Big Pharma Carve Out On Its Way.

An investment firm is interested in a Big Pharma carve-out.

cycle_mod.jpg

Team Spirit!

Management is thinking about taking over the business, with the help of an investment fund.

rope_mod.jpg

Selling Support Is What I Need.

CMO is looking into selling its sites, and needs support for its Vendor Due Dil.

Price Is What You Paid...

... and value is what you get like W. Buffet says. Learn more about our valuation services.